Interview by Newsweek, time to talk

Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

Our services include:

1. Process Development
2. Formulation Development
3. Analytical Development
...

small moleculepeptide
biologics

VialsPrefilled Syringe
Injection Pen 

• Azacitidine (Oncology) • Bortezomib (Oncology) • Fulvestrant (Oncology) • Pemetrexed (Oncology) • Ponatinib (Oncology) • Glucagon (Endocrinology) • Octreotide (Endocrinology) • Teriparatide (Osteoporosis)

Azacitidine inj

Bortezomib inj

Docetaxel inj

Doxorubicin inj

Epirubicin inj

Fulvestrant inj

Gemcitabine inj

...

Acyclovir inj

Colistin inj

Ganciclovir inj

Teicoplanin inj

Vancomycin inj

Levetiracetam inj

Valproate inj

...

API < USD 500 per gram, COA available Finished product

Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

Our services include:
1. Process Development
2. Formulation Development
3. Analytical Development
4. Small Scale Biologics / Injectable Production
5. Commercial Scale Injectable Production

6. Dedicated Oncology Production (API / Injectables)
7. Regulatory Affairs

Generic/Peptide/Biosimilar projects available for out-licensing
Oncology-Azacitidine, Bortezomib, Pemetrexed, Fulvestrant
Peptide-Glucagon, Teriparatide, Octreotide, Terlipressin
Biosimilar-Liraglutide, Ranibizumab, Denosumab
Others-Levetiracetam, Palonosetron, Valproate

Interviewee：Dr. Steve J. P. Hsu (President of Genovior Biotech)

CDMO